|AHFS/Drugs.com||International Drug Names|
|Elimination half-life||1.5 hours|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||562.15 g·mol−1|
|3D model (JSmol)|
Indometacin farnesil (INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon, respectively.